Gene therapy offers another promising avenue, with liver-directed delivery systems aiming to restore ABCC6 expression [5]. Although no curative treatment currently exists for PXE, a combination of targeted symptomatic management and emerging experimental strategies holds promise for altering the disease trajectory in the future. Here, ABCC6 is linked to Pseudoxanthoma elasticum.